Phenobarbital Global Market Report 2025

The phenobarbital market size has grown strongly in recent years. It will grow from $1.47 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be attributed to the widespread use in epilepsy management, the prevalence of epilepsy and seizure disorders, government supply programs, increasing demand in veterinary applications, and efforts toward achieving universal health coverage.

The phenobarbital market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth during the forecast period can be linked to the expansion of generic drug manufacturing, growing focus on neurological disease management, digital supply chain and e-pharmacy growth, regulatory changes favoring generic use, and stability in regulatory pathways for generics. Key trends in the forecast period include the development of easy-to-administer delivery forms, innovation in research and development, extended-release formulations, enhanced drug delivery systems, and investments in improving production techniques.

The rising prevalence of epilepsy is anticipated to drive the growth of the phenobarbital market. Epilepsy is a neurological condition marked by recurring, unprovoked seizures caused by abnormal brain activity. The increasing incidence of epilepsy is partly due to greater awareness, leading more individuals to recognize symptoms and seek medical attention, resulting in more reported cases. Phenobarbital, an anticonvulsant medication, helps control seizures by slowing down the activity of neurons in the brain. For example, a report from the Centers for Disease Control and Prevention (CDC) in May 2024 revealed that between 2021 and 2022, around 2.9 million adults in the U.S. were living with active epilepsy, representing approximately 1% of the adult population. As a result, the growing prevalence of epilepsy is expected to drive the demand for phenobarbital.

Key companies in the phenobarbital market are focusing on developing new treatments, such as phenobarbital sodium, to improve both the safety and effectiveness of therapies. Phenobarbital sodium is the sodium salt form of phenobarbital, commonly used as an anticonvulsant and sedative. It is primarily prescribed to manage seizures, especially in conditions such as epilepsy, and can also be used to treat anxiety, insomnia, and to induce sedation before medical procedures. In January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, launched SEZABY (phenobarbital sodium) in the U.S. This was the first FDA-approved medication specifically designed to treat seizures in both term and preterm neonates. SEZABY is free of benzyl alcohol and propylene glycol, making it safer for use in newborns. The drug received orphan drug designation and is supported by clinical data demonstrating its effectiveness in controlling neonatal seizures, addressing a critical unmet need in this vulnerable patient group.

In November 2022, Sun Pharmaceutical Industries Ltd. partnered with SPARC, an India-based biopharmaceutical company, to commercialize phenobarbital for injection in the U.S. This collaboration focuses on marketing a benzyl alcohol- and propylene glycol-free phenobarbital sodium injection to address the unmet need for an FDA-approved treatment for neonatal seizures, while also reducing the risk of neonatal gasping syndrome. SPARC specializes in developing innovative therapeutics.

Major players in the phenobarbital market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, H. Lundbeck A/S, Sandoz Group AG, Yashiro Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Par Pharmaceutical Inc., Shandong Xinhua Pharmaceutical Co. Ltd., Manus Aktteva Biopharma LLP, JPN Pharma Pvt. Ltd., Alkaloida Chemical Company Zrt., Harman Finochem Ltd.

North America was the largest region in the phenobarbital market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phenobarbital report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phenobarbital market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Phenobarbital is a long-acting barbiturate medication primarily used to control and prevent seizures, especially in the treatment of epilepsy. It is occasionally prescribed as a sedative for anxiety or to manage withdrawal symptoms. It works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits nerve activity in the brain, leading to a calming effect on the central nervous system and a reduced risk of seizures.

The main indications for phenobarbital are epilepsy and neonatal seizures. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures. It is available in various dosage forms such as tablets, capsules, and injectables, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is used in seizure management, anesthesia, sleep disorders, and alcohol withdrawal syndrome, serving a range of end users, including hospitals, clinics, research laboratories, and homecare settings.

The phenobarbital market research report is one of a series of new reports that provides phenobarbital market statistics, including phenobarbital industry global market size, regional shares, competitors with a phenobarbital market share, detailed phenobarbital market segments, market trends and opportunities, and any further data you may need to thrive in the phenobarbital industry. This phenobarbital market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The phenobarbital market consists of sales of products including phenobarbital tablets, phenobarbital oral elixir, phenobarbital injectables, veterinary phenobarbital products, and combination medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.